Leveraging Uncertainty Estimates for Drug Response Prediction in Cancer Cell Lines

Abstract Machine learning models for drug response prediction in cancer cell lines carry the potential to advance precision oncology by tailoring treatments to the molecular tumor profile. Their application is challenged by variability in prediction quality and distribution shifts between training and application. Uncertainty estimation provides more information on the predictive distribution than point estimates, enabling comprehensive decision support and downstream analysis of predictions. Yet, the most effective uncertainty estimator is domain-specific. In this work, we benchmark uncertainty-aware models for drug response prediction. We focus on epistemic uncertainty via ensemble agreement, and aleatoric uncertainty via distributional modeling, or both. We find that ensemble-based estimates are more sensitive to distribution shift and can flag out-of-distribution examples. In contrast, distributional models yield stronger prediction error reductions among high-confidence subsets. Despite higher computational cost, the combination can provide both advantages: an ensemble of neural networks that estimate a Gaussian predictive distribution can reduce the mean squared error by 64 percent when restricting predictions to the 10 percent most confident drug-cell line pairs, and reliably indicates distribution shifts and platform differences. Beyond benchmarking, probabilistic predictions can identify drugs whose uncertainty bounds overlap with therapeutically relevant ranges. We also show that uncertainty estimates enable a new dimension of model interpretability: by attributing predicted uncertainty to input features, we identify genes that signal unpredictability of drug response rather than sensitivity or resistance. We further demonstrate uncertainty-guided selection of measurements for active learning. In summary, including uncertainty in drug response prediction supports better-informed model application. The code is available at https://github.com/PascalIversen/LUDRP .

Authors

Institutions

Publication Details

Journal
Bioinformatics Advances
Published
2026-08-24
DOI
https://doi.org/10.1093/bioadv/vbag246
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Leveraging Uncertainty Estimates for Drug Response Prediction in Cancer Cell Lines

Bernhard Y. Renard, Pascal Iversen, Katharina Baum
Bioinformatics Advances
Computational Drug Discovery Methods
article

Leveraging Uncertainty Estimates for Drug Response Prediction in Cancer Cell Lines

Bernhard Y. Renard, Pascal Iversen, Katharina Baum
article en

Abstract

Abstract Machine learning models for drug response prediction in cancer cell lines carry the potential to advance precision oncology by tailoring treatments to the molecular tumor profile. Their application is challenged by variability in prediction quality and distribution shifts between training and application. Uncertainty estimation provides more information on the predictive distribution than point estimates, enabling comprehensive decision support and downstream analysis of predictions. Yet, the most effective uncertainty estimator is domain-specific. In this work, we benchmark uncertainty-aware models for drug response prediction. We focus on epistemic uncertainty via ensemble agreement, and aleatoric uncertainty via distributional modeling, or both. We find that ensemble-based estimates are more sensitive to distribution shift and can flag out-of-distribution examples. In contrast, distributional models yield stronger prediction error reductions among high-confidence subsets. Despite higher computational cost, the combination can provide both advantages: an ensemble of neural networks that estimate a Gaussian predictive distribution can reduce the mean squared error by 64 percent when restricting predictions to the 10 percent most confident drug-cell line pairs, and reliably indicates distribution shifts and platform differences. Beyond benchmarking, probabilistic predictions can identify drugs whose uncertainty bounds overlap with therapeutically relevant ranges. We also show that uncertainty estimates enable a new dimension of model interpretability: by attributing predicted uncertainty to input features, we identify genes that signal unpredictability of drug response rather than sensitivity or resistance. We further demonstrate uncertainty-guided selection of measurements for active learning. In summary, including uncertainty in drug response prediction supports better-informed model application. The code is available at https://github.com/PascalIversen/LUDRP .

Bioinformatics Advances
Mount Sinai Health System (US), Hasso Plattner Institute (DE), Freie Universität Berlin (DE), Icahn School of Medicine at Mount Sinai (US)
Quality Education
Openalex Percentile: Top 64%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.